September 18, 2009 14:40 ET

CEL-SCI's CEO Says H1N1 Flu Drug Candidate Could Propel Company Onto World Stage

LOS ANGELES, CA--(Marketwire - September 18, 2009) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a transcript of their interview with CEL-SCI Corporation's CEO, Geert Kersten.

CEL-SCI Corporation's (NYSE Amex: CVM) just received FDA approval to proceed with a clinical trial of its H1N1 flu drug candidate, testing its effect on white blood cells of patients who are hospitalized. The biotech firm said it is working on the next phase of the study and is preparing the drug's follow-up regulatory application.

"You have to consider that the 'bad' evolution of this virus is most likely to happen outside of this country," says Kersten. "That's where you're going to get re-assortment. We don't know what those death rates could be, but what you have from the current virus is high transmissibility in warm weather which has not been seen before in any other flu virus. If it picks up something nasty from another virus and that person gets on a plane, well then suddenly CEL-SCI could be the most important company in the world because there will be no one else who has done any work on this at all. Everyone would come to us."

The complete transcript is available now at BioMedReports.Com:

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

For more biomedical sector and investment news go to

Contact Information

  • Contact:
    Mike Havrilla
    Managing Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556